The Role of MRD Testing in Guiding Treatment in R/R MM: ASCO 2024 Updates from PERSEUS

Opinion
Video

Following ASCO 2024, Samer Al'Hadidi, MD, discusses recent updates from the PERSEUS trial evaluating the role of testing for minimal residual disease (MRD) in guiding treatment for relapsed/refractory multiple myeloma.

Video content above is prompted by the following question:

  • Please comment on the recent updates from the analysis of minimal residual disease (MRD) in the PERSEUS trial.
Recent Videos
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 5 experts on multiple myeloma
Surbhi Sidana, MD, spoke about multiple myeloma developments with the potential to impact clinical practice, particularly early line use of bispecific antibodies.
A panel of 5 experts on multiple myeloma
Surbhi Sidana, MD, discussed LINKER-MM1 trial efficacy findings, in which linvoseltamab was evaluated in patients with relapsed/refractory multiple myeloma.
Related Content
“I don't think [the CRL] impacts how I look at the data that is publicly available and the approval chances long term for linvoseltamab and how we might use it in the future,” said Surbhi Sidana, MD.

Linvoseltamab Still Efficacious Despite CRL in Multiple Myeloma

Roman Fabbricatore
September 3rd 2024
Article

“I don't think [the CRL] impacts how I look at the data that is publicly available and the approval chances long term for linvoseltamab and how we might use it in the future,” said Surbhi Sidana, MD.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®
May 6th 2024
Podcast

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

MRD May Predict Improved Outcomes in Multiple Myeloma

MRD May Predict Improved Outcomes in Multiple Myeloma

ONCOLOGY Staff
August 25th 2024
Article

Minimal residual disease as an end point in multiple myeloma has been widely discussed and was even a topic of a recent ODAC meeting.

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma

Joselle Cook, MBBS, Mayo Clinic;Matthew James Pianko, MD;Luciano Costa, MD, PhD;Timothy Schmidt, MD
August 14th 2023
Podcast

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Quadruplet Therapy May Be the New Frontline SOC in Multiple Myeloma

Quadruplet Therapy May Be the New Frontline SOC in Multiple Myeloma

ONCOLOGY Staff
August 23rd 2024
Article

Quadruplet therapy is making a run to be a potential standard of care in frontline multiple myeloma, according to a panel of experts.

The phase 1/2 LINKER-MM1 trial assessed linvoseltamab in relapsed/refractory multiple myeloma, of which the indication has been given a CRL by the FDA.

FDA Gives CRL to Linvoseltamab in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore;Ariana Pelosci
August 21st 2024
Article

The phase 1/2 LINKER-MM1 trial assessed linvoseltamab in relapsed/refractory multiple myeloma, of which the indication has been given a CRL by the FDA.